Skip to content
Agentic OS
Menu

Intelligence / Healthtech / New Clinical Trials / Medicovestor, Inc

Clinicaltrial registered2 Nov 2026

Medicovestor, Inc

2 Nov 2026: Trial registered · A Study of MC001 in Patients With Advanced or Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) and Other Folate Receptor Alpha (FRα)-Expressing Solid Tumors. Recorded in the ClinicalTrials.gov (US National Library of Medicine).

View the source record

Posted
2 Nov 2026
Title
A Study of MC001 in Patients With Advanced or Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) and Other Folate Receptor Alpha (FRα)-Expressing Solid Tumors
Conditions
Pancreatic Ductal Adenocarcinoma (PDAC), Advanced Solid Tumor Cancer, Metastatic Pancreatic Cancer, Metastatic Solid Tumors
Phase
Phase 1
Study Type
Interventional
Status
Not Yet Recruiting
Countries
United States
Country
United States
Reference
NCT07909356
Location
United States
What this signal means

A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.

  1. United States leads with 192 of 777, then China (171).
  2. 777 added in the 30 days to 18 Nov 2026.
Reach them with AOS

Find the decision makers at Medicovestor, Inc

AOS maps the buying committee, finds verified work emails and drafts outreach that cites this clinical signal, for your approval.

Start free

More from United States

New Clinical Trials

See all

Source: ClinicalTrials.gov (US National Library of Medicine), data to 18 Nov 2026. Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase. AOS shows what the public record says; it does not verify or endorse the company.